Organizational and direct support maintenance repair parts and special tools list (including depot maintenance repair parts and special tools) for viewers, driver's night vision, AN/VVS-2(V)1 (NSN 5855-00-629-5278), AN/VVS-2(V)2 (NSN 5855-01-057-1880), AN/VVS-2(V)3 (NSN 5855-01-105-7793), AN/VVS-2(V)1A (NSN 5855-01-096-0871), and AN/VVS-2(V)2A (NSN 5855-01-096-0872).

Includes index.

Operator's manual : viewers, driver's, night vision, AN/VVS-2(V)1 (NSN 5855-00-629-5278), AN/VVS-2(V)1A (NSN 5855-01-096-0871), AN/VVS-2(V)2 (NSN 5855-01-057-1880), AN/VVS-2(V)2A (NSN 5855-01-096-0872), AN/VVS-2(V)3 (NSN 5855-01-105-7793).

"August 1982."

A study of bakery contracts, covering retail driver salesmen, wholesale driver salesmen, route builders, swingmen, supervisors, supply drivers, route riders, helpers.

Cover title.

Driver performance measures for the safe performance curriculum /

Mode of access: Internet.

Classified driver licensing in the United States.

Mode of access: Internet.

Computer simulation of driver behavior during car following: a methodological study; final report,

Mode of access: Internet.

Interstate compacts for traffic safety: The driver license compact and The vehicle equipment safety compact.

Mode of access: Internet.

Alcohol and highway safety : professional papers on state and federal driver licensing programs.

Item 982-D-1

The Drunk driver and jail /

"DOT HS 806 765"--Vol. 5, p. [4] of cover.

A Guide to developing a community-based, designated driver program.

"DOT HS 808 137"--P. [4] of cover.

Driver Instruction; a Guide for Driver Education and Driver Training in California Schools

Mode of access: Internet.

Driver Licensing Laws Annotated; Annual Supplement

Supplements to National Committee on Uniform Traffic Laws and Ordinances. Driver Licensing Laws Annotated

The evolving profile, role and relevance of the medical director in a pharmaceutical company

Over the last years, operations in Pharmaceutical Companies have become more complex, trying to adapt to new demands of the market environment. Overall, the observed change of paradigm requires adapting, mainly by the setting of new priorities, diversification of investments, cost containment strategies, exploring new markets and developping new sets of skills. In this context, new functions have been created, the relevance of some has diminished, and the importance of others has arisen. Amongst these, the medical structure within a Pharmaceutical Company, increased to meet demands, with companies adopting different models to respond to these needs, and becoming a pillar to the business. Assuming the leading role within a medical department, the medical director function often lies in the shadow. It is a key function within Pharma Industry, either on a country or on a Global basis. It has evolved and changed in the past years to meet the constant demands of a changing environment. The Medical Director is a highly skilled and differeniated professional who provides medical and scientific governance within a Pharmaceutical company, since early stages of drug development and up to loss of exclusivity, not only but also by leading a team of other physicians, pharmacists or life scientists whose functions comprise specificities that the medical director needs to understand, provide input to, oversee and lead. As the organization of Pharmaceutical Companies tends to be different, in accordance to values, culture, markets and strategies, the scope of activities of a Medical Director can be broader or may be limited, depending on size of the organization and governance model, but they must fulfil a large set of requirements in order to leverage impact on internal and internal customers. Key technical competencies for medical directors such as an MD degree, a strong clinical foundation, knowledge of drug development, project and team management experience and written and verbal skills are relatively easy to define, but underlying behavioural competencies are more difficult to ascertain, and these are more often the true predictors of success in the role. Beyond seamless proficiency in technical skills, at this level interpersonal skills become far more important, as they are the driver and the distinctive factor between a good and an excelent medical director. And this has impact in the business and in the people doing it.

CALR mutation profile in Irish patients with myeloproliferative neoplasms

Insertion and/or deletion mutations of the CALR gene have recently been demonstrated to be the second most common driver mutations in the myeloproliferative neoplasms (MPNs) of essential thrombocythemia (ET) and primary myelofibrosis (PMF). Given the diagnostic and emerging prognostic significance of these mutations, in addition to the geographical heterogeneity reported, the incidence of CALR mutations was determined in an Irish cohort of patients with MPNs with a view to incorporate this analysis into a prospective screening program. A series of 202 patients with known or suspected ET and PMF were screened for the presence of CALR mutations. CALR mutations were detected in 58 patients. Type 1 and Type 1-like deletion mutations were the most common (n = 40) followed by Type 2 and Type 2-like insertion mutations (n = 17). The CALR mutation profile in Irish ET and PMF patients appears similar to that in other European populations. Establishment of this mutational profile allows the introduction of a rational, molecular diagnostic algorithm in cases of suspected ET and PMF that will improve clinical management.

Profile Of The Use Of Disease Modifying Drugs In The Brazilian Registry Of Spondyloarthritides.

Few studies have evaluated the profile of use of disease modifying drugs (DMD) in Brazilian patients with spondyloarthritis (SpA). A common research protocol was applied prospectively in 1505 patients classified as SpA by criteria of the European Spondyloarthropathies Study Group (ESSG), followed at 29 referral centers in Rheumatology in Brazil. Demographic and clinical variables were obtained and evaluated, by analyzing their correlation with the use of DMDs methotrexate (MTX) and sulfasalazine (SSZ). At least one DMD was used by 73.6% of patients: MTX by 29.2% and SSZ by 21.7%, while 22.7% used both drugs. The use of MTX was significantly associated with peripheral involvement, and SSZ was associated with axial involvement, and the two drugs were more administered, separately or in combination, in the mixed involvement (p < 0.001). The use of a DMD was significantly associated with Caucasian ethnicity (MTX , p = 0.014), inflammatory back pain (SSZ, p = 0.002) , buttock pain (SSZ, p = 0.030), neck pain (MTX, p = 0.042), arthritis of the lower limbs (MTX, p < 0.001), arthritis of the upper limbs (MTX, p < 0.001), enthesitis (p = 0.007), dactylitis (MTX, p < 0.001), inflammatory bowel disease (SSZ, p < 0.001) and nail involvement (MTX, p < 0.001). The use of at least one DMD was reported by more than 70% of patients in a large cohort of Brazilian patients with SpA, with MTX use more associated with peripheral involvement and the use of SSZ more associated with axial involvement.